TRex Bio (NASDAQ:TRXB) Stock Rated Hold in New Coverage at Zacks Research

Research analysts at Zacks Research initiated coverage on shares of TRex Bio (NASDAQ:TRXB) in a note issued to investors on Tuesday, Zacks reports. The firm set a “hold” rating on the stock.

Several other research analysts have also issued reports on the company. JPMorgan Chase & Co. initiated coverage on TRex Bio in a research note on Tuesday. They set an “overweight” rating and a $20.00 price objective for the company. Wedbush initiated coverage on shares of TRex Bio in a research note on Monday. They issued an “outperform” rating and a $30.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of TRex Bio in a research note on Tuesday. They issued an “overweight” rating on the stock. Evercore assumed coverage on shares of TRex Bio in a report on Tuesday. They issued a “strong-buy” rating on the stock. Finally, Stifel Nicolaus started coverage on shares of TRex Bio in a research report on Tuesday. They set a “buy” rating and a $39.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $29.67.

TRex Bio Trading Down 1.3%

TRex Bio stock opened at $13.55 on Tuesday. TRex Bio has a one year low of $12.50 and a one year high of $16.56.

Insider Activity

In related news, major shareholder Alexandria Venture Investments bought 178,571 shares of TRex Bio stock in a transaction dated Tuesday, October 13th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the transaction, the insider owned 1,346,501 shares of the company’s stock, valued at approximately $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.